Skip to main content
OpenTrials
Completed

NCT Number: NCT06654869

Effects of Laughter Yoga on Symptom Severity, Hope, and Life Engagement in Patients Undergoing Chemotherapy; A Randomized Controlled Study

Non-pharmacological interventions that promote positive emotional states and coping may play a critical role in care of cancer patients undergoing chemotherapy. .This study aimed to evaluate the effects of laughter yoga on symptoms, hope, and life engagement levels in cancer patients undergoing chemotherapy. Conducted between January and June 2025 at the chemotherapy unit of Atatürk University Research Hospital in Türkiye, this randomized controlled trial included 55 chemotherapy patients who were randomly assigned to an intervention group (n = 27) receiving 40-minute weekly laughter yoga sessions for four weeks or to a control group (n = 28) receiving routine care. Symptom severity, hope, and life engagement were measured at baseline and after four weeks using the Edmonton Symptom Assessment Scale (ESAS), Herth Hope Scale (HHS), and Life Engagement Scale (LES). Post-intervention analyses revealed statistically significant improvements in the intervention group compared to the control group. Patients who received laughter yoga reported significantly lower symptom severity on the ESAS (p < 0.05), along with significantly higher levels of hope and life engagement as measured by the HHS and LES, respectively (p < 0.05).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Atatürk Üniversitesi

Erzurum, Yakutiye, 25080, Turkey (Türkiye)

About this study

Sample Size Calculation:

The sample size was determined through an a priori power analysis using G*Power software (version 3.1.2). The test family was "t tests" and the statistical test was "Means: Difference between two independent means (two groups)". Based on Cohen's standard effect size references (Faul et al., 2007; Çapık, 2014), it was determined that a total of 52 participants (26 per group) would be sufficient to achieve 80% power with a large effect size (two-tailed, Cohen's d = 0.80, α = 0.05). The choice of a large effect size was justified by recent evidence from laughter interventions in cancer (Qu et al., 2025; Lin et al., 2024; Han et al., 2023). To account for a potential 15% attrition rate, 8 additional participants were included, resulting in a total sample size of 60 individuals (Capik, 2014). Following the completion of the study, the effect sizes for each variable were reported in their respective tables.Inclusion criteria: (1) age ≥18, (2) pathologically confirmed cancer diagnosis, (3) be able to communicate, and (4) voluntary participation. Exclusion criteria: (1) psychiatric disorder, (2) treatments other than chemotherapy, (3) severe psychiatric illness, (4) hearing or vision loss, (5) prior laughter therapy experience, or (6) unstable clinical condition. Discontinuation Criteria: (1) withdrawal request, (2) worsening of clinical condition, (3) change in treatment protocol.Due to the nature of the laughter yoga intervention, participants and the first author (who performed the sessions) could not be blinded. After baseline assessments, 60 eligible patients were randomized into intervention (n=30) and control (n=30) groups with a 1:1 allocation ratio using a computer-generated random number list (randomizer.org). Due to the nature of the laughter yoga intervention, participants and the first author (who performed the sessions) could not be blinded. After obtaining voluntary consent, eligible patients were randomized into intervention (n=30) and control (n=30) groups with a 1:1 allocation ratio using a computer-generated random number list (randomizer.org). To ensure allocation concealment, randomization was managed by an independent researcher who did not recruit patients or perform the sessions. Once a patient was enrolled, the independent researcher provided the group assignment to the first researcher. This centralized approach prevented the first researcher from knowing the sequence in advance, thereby reducing potential selection bias. Immediately following randomization, but prior to the collection of pre-test and the commencement of the intervention, five patients (3 from the intervention group and 2 from the control group) were excluded due to unforeseen changes in their medical treatment protocols. Since these individuals left the study before any baseline or post-test assessments could be conducted, their data were unavailable for inclusion. Consequently, a per-protocol analysis was performed with the remaining 55 patients (27 intervention, 28 control) who completed the trial. To minimize bias, data analysis was conducted by an independent statistician who remained blinded to the group assignments throughout the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(1) age ≥18, (2) pathologically confirmed cancer diagnosis, (3) be able to communicate, and (4) voluntary participation.

Exclusion criteria

(1) psychiatric disorder, (2) treatments other than chemotherapy, (3) severe psychiatric illness, (4) hearing or vision loss, (5) prior laughter therapy experience, or (6) unstable clinical condition.

Discontinuation Criteria: (1) withdrawal request, (2) worsening of clinical condition, (3) change in treatment protocol.

Treatment and study plan

lauhgter yoga

Behavioral

include laughter yoga effects on cancer patients' symptom management

Primary outcomes

  1. Edmonton Symptom Assesment Scale (ESAS)

    Time frame: 4 weeks

    Bruera et al. (1991) to evaluate nine symptoms commonly seen in cancer patients. These symptoms are pain, fatigue, nausea, sadness, anxiety, insomnia, loss of appetite, feeling good, shortness of breath and other problems. In the other problems section of the scale, 2 additional symptoms seen in patients by researchers (feeling of thirst and discomfort due to catheters and catheters) were added in accordance with literature information. The severity of each symptom is evaluated with numerical numbers from 0 to 10. A score of 0 indicates that there is no symptom, a score of 10 indicates that the symptom is felt very severely, and the severity of the symptom increases from 0 to 10.

  2. Life Engagement Scale

    Time frame: 4 weeks

    The Life Engagement scale, developed by Scheier et al. (2006) to assess individuals' life goals and whose Turkish validity and reliability were determined by Akın et al., is a measurement tool consisting of 6 items and a single dimension (life engagement). The scale has a 5-point scale ("1" I completely disagree, "5" I completely agree). Items 1, 3 and 5 are reverse coded in the scale. Increasing scores indicate a high level of life engagement.

  3. Herth Hope Scale

    Time frame: 4 weeks

    The Herth Hope Scale was developed by Kaye Herth. The scale consists of 30 items. Each item has four options: "Never " "Rarely appropriate," "Sometimes" and "Always " . The corresponding scores are 0, 1, 2, and 3, respectively. The respondent is asked to mark a single option for each item. The scale consists of 3 sub-dimensions. These are "Future," "Positive Readiness and Expectation," and "Relationships Between Oneself and Those Around Oneself." The "Future" sub-dimension measures the cognitive-temporal dimension of hope, the "Positive Readiness and Expectation" sub-dimension measures the emotional-behavioral dimension of hope, and the "Relationships Between Oneself and Those Around Oneself" sub-dimension measures the dimension of hope related to relationships and the conditions in which it exists. The total hope score varies between 0-90, and the total score of each subscale varies between 0-30. High scores, It shows that hope is high.

Sponsors and collaborators

Lead sponsor

Ataturk University

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 23, 2024
Registry last updated
Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.